Cargando…
ODP495 Medullary Thyroid Cancer Outcome in a Tertiary Care Centre in Atlantic Canada
BACKGROUND: Medullary thyroid carcinoma (MTC) constitutes around 1-2% of all thyroid cancer with a paucity of published data. Distinctively, MTC has a strong genetic component with oncogene mutations. For AJCC stages I, II, III, and IV, 5-year overall survival (OS) rates are 100, 90, 86.5 and 55.5%....
Autores principales: | Rajaraman, Kye, Devereaux, Emily, Rajaraman, Murali, Imran, Syed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625371/ http://dx.doi.org/10.1210/jendso/bvac150.1595 |
Ejemplares similares
-
ODP477 Ectopic Cushing's Syndrome Due to Medullary Thyroid Cancer
por: Mateen, Abdul, et al.
Publicado: (2022) -
SAT526 Limited Utility of Routine Neck Ultrasound Follow-up in Advanced Stage Differentiated Thyroid Cancer
por: Munro, Vicki, et al.
Publicado: (2023) -
ODP585 Occult metastatic medullary thyroid carcinoma without detectable primary tumor.
por: Chevais, Anastassia, et al.
Publicado: (2022) -
ODP466 Case of Sporadic Medullary Thyroid Cancer Detected by Serum Calcitonin Measurement
por: Juneau, Andrea Kate, et al.
Publicado: (2022) -
ODP450 A Case of Metastatic Medullary Thyroid Cancer Presenting with Pathologic Hip Fracture
por: Watari, Jessica, et al.
Publicado: (2022)